SR One is a transatlantic biotech venture capital firm focused on building elite biotechnology companies that translate innovative science into meaningful patient impact. As the former corporate venture arm of GSK, they leverage deep scientific and operational expertise to invest in both early-stage and growth-stage opportunities. Their unique value proposition stems from their long-standing industry presence, extensive network, and hands-on approach to company building, from discovery through commercialization.